2 October 2020 - - A US affiliate of Israeli drugmaker Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) has made available the first Food and Drug Administration -approved generic versions of Truvada and Atripla tablets, the company said.

With 1.2 m people currently living with HIV-1 in the US, Teva is committed to increasing access to critical HIV therapies.

Despite significant advances in the treatment and prevention of HIV over the last two decades, there are still 12.6 m people globally who are unable to obtain treatment.

With the introduction of these new generic HIV treatment options, Teva strives to further increase access to important therapies.

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are expected to be available through retailers and wholesalers at a Wholesale acquisition Cost of USD 48.51 per tablet.

Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are expected to be available through retailers and wholesalers at a WAC of USD 78.86 per tablet.

Actual costs to individual patients and providers are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply.

Savings on out-of-pocket costs may vary depending on the patient's insurance payer and eligibility for participation in the assistance program.

Severe acute exacerbations of hepatitis B have been reported in HBV-infected individuals who have discontinued emtricitabine and tenofovir disoproxil fumarate tablets.

Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals who are infected with HBV and discontinue emtricitabine and tenofovir disoproxil fumarate tablets. If appropriate, anti-hepatitis B therapy may be warranted.
 
Emtricitabine and tenofovir disoproxil fumarate tablets used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use.